Completed NA INTERVENTIONAL 4-arm NCT00898950

Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes

The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk

Sponsor: University of Portsmouth

Conditions Diabetes Type 2

Interventions Aspirin placebo tablet

Updated 5 times since 2017 Last updated: May 11, 2009 Started: Aug 31, 2004 Primary completion: Jul 31, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Diabetes Type 2 and is currently completed. University of Portsmouth leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jan 2017 — Jan 2021 [monthly]

Completed NA

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Portsmouth

Data source: University of Portsmouth

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portsmouth, United Kingdom